Journal article icon

Journal article

Fcγ receptor antigen targeting potentiates cross-presentation by human blood and lymphoid tissue BDCA-3+ dendritic cells

Abstract:

The reactivation of human cytomegalovirus (HCMV) poses a serious health threat to immune compromised individuals. As a treatment strategy, dendritic cell (DC) vaccination trials are ongoing. Recent work suggests that BDCA-3+ (CD141+) subset DCs may be particularly effective in DC vaccination trials. BDCA-3+ DCs had however been mostly characterized for their ability to cross-present antigen from necrotic cells. We here describe our study of human BDCA-3+ DCs in elicitation of HCMV-specific CD...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDORMS
Sub department:
Kennedy Institute for Rheumatology
Role:
Author
Expand authors...
Publisher:
American Society of Hematology Publisher's website
Journal:
Blood Journal website
Volume:
120
Issue:
26
Pages:
5163-5172
Publication date:
2012-10-23
Acceptance date:
2012-10-12
DOI:
EISSN:
1528-0020
ISSN:
0006-4971
Pmid:
23093620
Source identifiers:
693484
Language:
English
Keywords:
Pubs id:
pubs:693484
UUID:
uuid:b23e3c08-dda6-49f5-ae31-7acf28b7d7db
Local pid:
pubs:693484
Deposit date:
2017-06-12

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP